Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
The Firm is currently investigating Pradaxa lawsuits on behalf of individuals who suffered life-threatening internal bleeding, allegedly due to Pradaxa.
New York, New York (PRWEB) March 03, 2013
Pradaxa lawsuits continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court documents, the next Status Conference in the Pradaxa litigation has been scheduled for March 14, 2013. More than 170 lawsuits have been filed in the litigation by plaintiffs who allegedly suffered serious, life-threatening episodes of Pradaxa bleeding. The Pradaxa lawsuits further allege that Boehringer Ingelheim sold the blood thinner despite knowing it could cause fatal bleeding in some patients, and failed to adequately warn that there was no readily-available antidote for Pradaxa bleeding. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation — MDL No. 2385)
“Pradaxa bleeding is a frightening side effect, especially because there is no easy way to remedy this occurrence. We are pleased to see this litigation is moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to alleged victims of Pradaxa side effects.
Pradaxa was approved for sale by the U.S. Food & Drug Administration (FDA) in October 2012 to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation. According to a recent Bloomberg report, the FDA received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.*
Pradaxa was positioned as an improvement over decades-old warfarin, but an analysis published in the latest QuarterWatch Report from the Institute for Safe Medicine Practices (ISMP) found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.** Warfarin bleeding can be stopped via the administration of vitamin k. However, there is no readily available antidote for Pradaxa bleeding. Dialysis can be used to remove Pradaxa from the blood stream. However, a study published last May in the journal, Neurology, found this treatment is risky and may not be administered in enough time to stop Pradaxa bleeding.** *
According to court documents, the first trials in the federal Pradaxa litigation are scheduled to begin in September 2014. Victims of serious Pradaxa bleeding may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. To learn more about filing a Pradaxa lawsuit, please visit our website http://www.consumerinjurylawyers.com/, or call 1-877-779-1414 to speak with one of our attorneys today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-lawsuit/pradaxa-bleeding/prweb10491817.htm